Natural inhibitors for severe acute respiratory syndrome coronavirus 2 main protease from Moringa oleifera, Aloe vera, and Nyctanthes arbor-tristis: molecular docking and ab initio fragment molecular orbital calculations

Divya Shaji1 · Ryo Suzuki1 · Shohei Yamamoto1 · Daisuke Orihashi1 · Noriyuki Kurita1

Received: 20 May 2022 / Accepted: 25 July 2022 / Published online: 1 August 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
The novel coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide, and new drug treatments for COVID-19 are urgently required. To find the potential inhibitors against the main protease (Mpro) of SARS-CoV-2, we investigated the inhibitory potential of naturally occurring compounds from the plants Moringa oleifera, Aloe vera, and Nyctanthes arbor-tristis, using molecular docking, classical molecular mechanics optimizations, and ab initio fragment molecular orbital (FMO) calculations. Of the 35 compounds that we simulated, feralolide from Aloe vera exhibited the highest binding affinity against Mpro. Therefore, we proposed novel compounds based on the feralolide and investigated their binding properties to Mpro. The FMO results indicated that the introduction of a hydroxyl group into feralolide significantly enhances its binding affinity to Mpro. These results provide useful information for developing potent Mpro inhibitors.

Keywords SARS-CoV-2 · Main protease · In silico drug design · Medicinal plants · Molecular docking · Fragment molecular orbital calculations

Introduction
The novel coronavirus disease 2019 (COVID-19) responsible for the ongoing pandemic was first reported in December 2019 [1]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has spread rapidly around the world [2, 3]. It is an enveloped positive-sense single-stranded RNA virus and belongs to the Coronaviridae family, which causes a wide range of infections [4]. It contains one of the coronavirus nonstructural proteins, which is known as the main protease (Mpro). Mpro cleaves the viral polyproteins, pp1a, and pp1ab, into 16 non-structural proteins that are important for viral replication and maturation. Moreover, Mpro plays an important role in virus entry into host cells. Therefore, Mpro is a potential target for drugs to treat coronavirus infection because inhibition of Mpro halts virus entry and subsequent replication [5]. Currently, there is no effective antiviral therapy for COVID-19. Although vaccines have been developed against it, their safety and long-term effectiveness are still unclear [6], and no vaccine is 100% protective. To address these problems, we focused on identifying natural compounds that inhibit the Mpro of SARS-CoV-2 as potential drug leads based on the ab initio molecular simulations.

Medicinal plants are a valuable source of therapeutic agents and new leads for drug discovery [6, 7]. Approximately, 85% of the world’s population depends on medicinal plants for primary health care needs, and 80% of all synthetic drugs are derived from compounds found in medicinal plants [7]. Natural medicines are effective, safe, and affordable and have fewer side effects compared with synthetic drugs [8].

Aloe vera, also called Aloe barbadensis Miller, a species within the Asphodelaceae family, is a very short-stemmed, perennial, xerophytic, and succulent plant with triangular, green fleshy leaves [9, 10]. It is the most common aloe variety and contains a wide diversity of bioactive compounds including terpenoids, lectins, flavonoids, anthraquinones,
fatty acids, polysaccharides, sterols, tannins, enzymes, vitamins, and minerals [8, 11]. It has previously been reported to have antiviral, antimicrobial, anti-inflammatory, and anti-diabetic effects [8, 12, 13]. The antiviral activity of Aloe vera is due to its content of anthraquinones, flavonoids, minerals, vitamins, phenolic acids, sterols, and polysaccharides [8, 13]. Aloe-emodin (A10 of Fig. 1), an anthraquinone present in Aloe vera, has been reported to have antiviral activity against the following viruses: herpes simplex types 1 and 2, varicella-zoster, pseudorabies, and influenza [13, 14]. Substances extracted from Aloe vera leaves have antiviral effects against human cytomegalovirus in vitro [15]. In addition, Rezazadeh et al. have investigated the anti-herpes simplex virus type 1 activity of Aloe vera gel in in vitro cell culture [16]. Recently, Gansukh et al. have reported the ultrasound-mediated anti-influenza activity of the anthraquinones aloin and aloe-emodin (A10) from Aloe vera [17].

Nyctanthes arbor-tristis, commonly known as night jasmine, is a traditional medicinal plant that belongs to the family Oleaceae [18–20]. This plant is native to India and found in gardens as ornamental plant with high medicinal value in Ayurveda, a form of alternative medicine originating in India. It is widely distributed in the southern sub-Himalayan regions, as far as Godavari [19, 20]. Flavonoids, steroids, terpenes, alkaloids, and aliphatic compounds have been isolated from different tissues of Nyctanthes arbor-tristis. The main classes of medicinally interesting chemicals produced by this plant are alkaloids and glycosides [20]. Various studies on the pharmacological action of Nyctanthes arbor-tristis extracts have been reported, including antibacterial,
The compounds extracted from different tissues of *Aloe vera* and *Nyctanthes arbor-tristis* have shown inhibitory activity against encephalomyocarditis virus and Semliki Forest virus [20–22].

In previous molecular simulations [23] based on the molecular docking and ab initio fragment molecular orbital (FMO) methods, we investigated the binding properties of compounds extracted from *Moringa oleifera* to the Mpro of SARS-CoV-2. *Moringa oleifera* is a plant belonging to the Moringaceae family and has antifungal, antioxidant, anti-bacterial, anti-inflammatory, diuretic, and hepato-protective properties. Of the 12 natural products extracted from *Moringa oleifera*, the compound niaziminin (M9 shown in Fig. S1 of Supplementary material) has been found to have the highest binding affinity to the Mpro. Therefore, we have proposed novel compounds based on the structure of niaziminin and examined their binding properties to the Mpro, revealing that the addition of a hydroxyl group to niaziminin enhances its binding affinity to the Mpro.

The present study aims to extend this work to *Aloe vera* and *Nyctanthes arbor-tristis* to find novel compounds with higher binding affinities to the Mpro. To precisely investigate the binding properties of the natural products to the Mpro, we here performed a combination of approaches, including molecular docking, molecular mechanics (MM) optimization, and ab initio FMO calculations. The results revealed that feralolide (A14 of Fig. 1) from *Aloe vera* exhibits the highest binding affinity to the Mpro. Therefore, it is likely to be a potent Mpro inhibitor and a drug lead compound. Next, we proposed the novel compounds based on feralolide (A14) and investigated their binding properties. In addition, we conducted molecular dynamics (MD) simulations to confirm the stability of our proposed compounds at the ligand-binding pocket of the Mpro. Based on the FMO and MD results, we proposed some derivatives of natural compounds as candidates for potent inhibitors against the Mpro of SARS-CoV-2.

**Details of the molecular simulations**

**Modeling of the plant compounds and the main protease**

The compounds extracted from different tissues of *Aloe vera* [8, 11, 12, 24–26] and *Nyctanthes arbor-tristis* [18–20, 27–30] were selected from the literature and filtered using Lipinski’s rule of five [31], their three-dimensional (3D) structures were downloaded from the PubChem database [32]. The SwissADME web tool [33] was used to calculate the properties of the selected compounds from their SMILES (simplified molecular-input line-entry system) strings.

The structures of the selected compounds were fully optimized using the B3LYP/6-31G (d, p) method of the ab initio molecular orbital calculation program Gaussian 09 (G09) [34]. The charge distribution of each optimized structure was evaluated using the restrained electrostatic potential (RESP) analysis [35] using G09 [34] with the HF/6-31G (d) method, and the RESP charges were used as the charge parameters in the MM force fields of the compounds. These RESP charges are essential for the docking simulations, MM optimizations of the Mpro–ligand complexes, to precisely describe the electrostatic interactions between the compounds and the Mpro.

The 3D structure of the Mpro [36] was downloaded from the Protein Data Bank (PDB) as PDB ID: 6LU7 [37]. This protein has seven histidine (His) residues, each of which can exist in three different protonation states (i.e., Hid, Hie, and Hip) depending on the acidity of the surrounding environment. When the acidity of the environment is below pH6, a His residue tends to be in the protonated Hip state, whereas other His residues in the same protein could still be in the Hid or Hie state depending on the local structure around them. We used the PROPKA3.1 software [38, 39] to predict the exact protonation state of the His residues of Mpro. Of the seven His residues, only His64 was assigned as Hip; His41, His80, His163, and His172 were assigned to the Hid state, whereas His164 and His246 were assigned to the Hie state considering the local structure around these His residues. The ionized state was adopted for the remaining ionizable amino acid residues in the Mpro.

**Molecular docking of the compounds to the main protease and MM optimization**

To find the best inhibitors in the Mpro binding site, we conducted molecular docking simulations using the program AutoDock4.2.6 [40]. In the docking simulations, the size of the grid box was set to 19.5 × 19.5 × 19.5 Å³, which was almost 1.5 times the size of the compound, and the center of the grid box was set to the center of the compound in the co-crystallized Mpro–compound complex (PDB ID: 6LU7). The number of created candidate poses was 256, and the threshold distance for clustering these poses was set as 1.5 Å. The maximum number of energy evaluations (ga_num_evals) for each run was set as 2,500,000. From the various clusters generated by AutoDock4.2.6 [40], we selected the three clusters with the largest number of poses, and the representative structures of these clusters were used in the subsequent MM and FMO calculations.

To obtain stable structures for the Mpro–ligand complexes, the representative structures of the clusters obtained from the docking simulations were fully optimized in water using the classical MM method. In the MM optimizations, approximately 1800 water molecules existing within 8 Å of
the surface of the complex were explicitly considered. The MM and MD simulation program AMBER12 [41] was used. The AMBER FF99-SBLIN force field [42], TIP3P model [43], and general AMBER force field [44] were assigned to the Mpro, water molecules, and compounds, respectively. The criterion for the convergence of structure optimization was set as 0.0001 kcal/mol/Å.

**Ab initio FMO calculations for the main protease–ligand complexes**

To clarify the specific interactions and binding affinity of each compound to the Mpro, we investigated the electronic properties of the Mpro–ligand complex with explicit waters using the ab initio FMO method [45]. This method has obtained accurate results, comparable with those from experiments, for many biomolecules. As water molecules can make specific contributions to the interactions between the Mpro and a compound, water molecules existing within 10 Å of each compound were considered explicitly. The number of water molecules used in the FMO calculations was approximately 150 for all clusters. To predict the binding affinity of each compound to the Mpro, we evaluated the total inter-fragment interaction energies (IFIEs) [46] between the compounds and the Mpro residues using the ab initio FMO method [45].

In the present study, we did not consider the effect of entropy on the binding affinity because a vibrational analysis for the solvated Mpro–ligand complex would not have been practical when using the ab initio FMO method. In addition, the entropic effect was unlikely to be markedly different for each of the compounds, as they had similar chemical structures and would bind to the same site in the Mpro. Therefore, we investigated the total IFIEs between the Mpro residues and each compound using the ab initio FMO calculations and estimated the trend of binding affinity, assuming that the entropic effect was the same for each compound.

In the FMO calculations, the MP2/6-31G (d) method [47, 48] of the ABINIT-MP version 6.0 FMO calculation program [49] was used. Each amino acid of the Mpro, compound, and each water molecule were assigned as fragments in the FMO calculations. This fragmentation enabled us to analyze the interactions between each Mpro residue and the compound, including any effects due to the solvating water molecules.

In our previous study [50], we investigated the binding of ligands to the androgen receptor protein using the same FMO calculations. The evaluated total IFIEs of the ligands with the androgen receptor residues were confirmed to correlate well with the binding affinities of these ligands obtained experimentally. The coefficient of determination was 0.94 using all nine of the ligands studied, confirming that our evaluated total IFIEs correlated well with the observed binding affinities of these ligands for the androgen receptor. Therefore, the present FMO calculations are expected to estimate the binding affinity of the compounds and the Mpro accurately.

**Results and discussion**

**Optimized structures of the main protease–ligand complexes**

In our previous molecular simulations [23], we considered 12 natural compounds extracted from *Moringa oleifera* and investigated their binding affinities to the Mpro. Their chemical properties and structures are shown in Table S1 and Fig. S1 of the Supplementary material (SM). In addition, in the present study, we considered 14 compounds from

---

**Fig. 2** Chemical structures of the compounds extracted from *Nyctanthes arbor-tristis*
Aloe vera and 9 compounds from Nyctanthes arbor-tristis as candidate inhibitors against Mpro. Their pharmacokinetic properties evaluated using the SwissADME web tool [33] are listed in Tables S2 and S3 of SM and their chemical structures are shown in Figs. 1 and 2, respectively.

At first, the structures of the compounds were optimized, and the RESP charges were evaluated by G09 [34]. Using the optimized structure and RESP charge, each compound was docked into the binding site of the Mpro using the AutoDock4.2.6 program [40]. The candidate structures of

| Compound | Cluster | BE  | Poses | Residues involved in H-bonds | IFIE  |
|----------|---------|-----|-------|-----------------------------|-------|
| A1       | 1       | −3.31 | 32    | No H-bond                   | −22.5 |
|          | 2       | −3.19 | 75    | Gln189                       | −43.4 |
|          | 4       | −2.89 | 108   | Cys145                       | −57.0 |
| A2       | 1       | −3.58 | 78    | Ser144                       | −53.8 |
|          | 2       | −3.34 | 38    | Leu141, Cys145, Glu166       | −101.1|
|          | 3       | −3.26 | 87    | Asn142, Met165, Glu166       | −96.2 |
| A3       | 1       | −3.43 | 65    | Glu166                       | −97.0 |
|          | 2       | −3.04 | 70    | Cys145, Glu166, Leu167       | −99.4 |
|          | 13      | −2.4  | 35    | Asn142                       | −36.0 |
| A4       | 1       | −3.52 | 243   | Asn142, Glu166               | −70.0 |
|          | 2       | −3.29 | 1     | Hie164, Met165               | −41.1 |
|          | 3       | −3.20 | 12    | Thr24, Thr25, Thr45, Ser46   | −54.6 |
| A5       | 1       | −4.00 | 174   | Glu166                       | −55.2 |
|          | 3       | −3.72 | 62    | Thr190, Ala191               | −39.9 |
|          | 4       | −3.65 | 11    | Gln192, Ala193               | −49.2 |
| A6       | 1       | −3.61 | 148   | Asn142, Glu166               | −106.1|
|          | 2       | −3.46 | 93    | Asn142, Ser144, Glu166       | −116.8|
|          | 3       | −3.23 | 15    | Glu166, Leu167, Arg188, Gln189| −70.8 |
| A7       | 1       | −6.02 | 234   | No H-bond                    | −41.4 |
|          | 2       | −5.78 | 2     | No H-bond                    | −40.5 |
|          | 3       | −5.67 | 20    | Met17, Val18                 | −59.1 |
| A8       | 1       | −5.10 | 200   | No H-bond                    | −51.0 |
|          | 3       | −4.86 | 22    | Hie164, Met165, Glu166       | −94.5 |
|          | 4       | −4.70 | 28    | Hid41                        | −51.4 |
| A9       | 1       | −4.80 | 161   | Leu141, Asn142, Glu166       | −78.1 |
|          | 4       | −4.31 | 40    | Cys145, Glu166               | −56.5 |
|          | 6       | −4.22 | 36    | No H-bond                    | −50.6 |
| A10      | 1       | −4.41 | 229   | Cys145, Glu166, Hid172       | −112.1|
|          | 4       | −3.92 | 20    | Thr26, Leu27                 | −78.6 |
|          | 5       | −3.87 | 3     | Asn142, Glu166               | −90.6 |
| A11      | 1       | −4.67 | 115   | Asn142, Ser144, Glu166, His172| −95.7 |
|          | 3       | −4.33 | 55    | No H-bond                    | −55.9 |
|          | 5       | −4.03 | 32    | Hid41, Asn142, Gln189        | −71.7 |
| A12      | 1       | −5.05 | 167   | Hid41, Asn142, Glu166        | −91.2 |
|          | 2       | −4.93 | 27    | Asn142, Glu166, Gln189       | −122.6|
|          | 3       | −4.81 | 39    | Glu166, Gln189               | −78.8 |
| A13      | 1       | −5.26 | 136   | Glu166                       | −70.0 |
|          | 3       | −5.20 | 32    | Thr26                        | −69.9 |
|          | 5       | −4.75 | 31    | Cys145                       | −73.8 |
| A14      | 1       | −4.75 | 39    | Glu166, Gln189               | −111.5|
|          | 6       | −4.30 | 23    | Thr26, Leu27, Asn142, Glu166, Leu167 | −150.1 |
|          | 12      | −4.07 | 24    | Thr24, Thr25, Asn142         | −102.9|
Table 2 This table shows the compounds extracted from Nyctanthes arbor-tristis with their lowest binding energy (BE) (kcal/mol), the number of poses, and the Mpro residues involved in H-bonds for the selected clusters obtained using the AutoDock4.2.6 program [40]. The 256 poses created were classified into several clusters based on the structural similarity, and each cluster was ranked in the order of the BE between the Mpro and the compound. We selected three clusters with the largest number of poses and evaluated the total IFIE (kcal/mol) of each compound with all the Mpro residues using the FMO method. These values are listed in the last column.

| Compound | Cluster | BE  | Poses | Residues involved in H-bonds | IFIE  |
|----------|---------|-----|-------|-----------------------------|-------|
| N1       | 1       | −3.75 | 85    | No H-bond                   | −43.2 |
|          | 5       | −3.24 | 17    | No H-bond                   | −43.6 |
|          | 9       | −3.04 | 32    | Glu166                       | −36.7 |
| N2       | 2       | −2.98 | 100   | Glu166                       | −75.5 |
|          | 3       | −2.96 | 44    | No H-bond                   | −24.3 |
|          | 5       | −2.87 | 38    | No H-bond                   | −33.4 |
| N3       | 1       | −3.69 | 53    | Glu166                       | −82.8 |
|          | 2       | −3.66 | 47    | Leu141, Glu166               | −87.0 |
|          | 4       | −3.45 | 47    | Thr26                        | −57.7 |
| N4       | 1       | −4.54 | 24    | No H-bond                   | −28.7 |
|          | 2       | −4.54 | 3     | No H-bond                   | −23.3 |
|          | 3       | −4.48 | 29    | No H-bond                   | −33.6 |
| N5       | 1       | −2.87 | 78    | No H-bond                   | −25.3 |
|          | 2       | −2.78 | 160   | Glu166                       | −56.0 |
|          | 3       | −2.45 | 23    | Asn142                       | −40.2 |
| N6       | 1       | −3.31 | 67    | Gln189                       | −41.6 |
|          | 2       | −3.13 | 46    | Gln166                       | −57.2 |
|          | 4       | −3.05 | 86    | Gln189                       | −52.8 |
| N7       | 1       | −4.9  | 78    | No H-bond                   | −50.0 |
|          | 2       | −4.69 | 74    | Asn142, Gly143              | −64.7 |
|          | 3       | −4.66 | 47    | Asn142, Gly143              | −66.9 |
| N8       | 1       | −6.35 | 255   | No H-bond                   | −173.7|
|          | 2       | −5.49 | 1     | No H-bond                   | −109.6|
| N9       | 1       | −4.85 | 196   | His172                      | −74.5 |
|          | 2       | −4.65 | 19    | Gly143, Glu166              | −94.8 |
|          | 3       | −4.40 | 17    | Thr26, His172               | −75.0 |

The results of the docking, MM, and FMO calculations for the compounds from Aloe vera and Nyctanthes arbor-tristis are listed in Tables 1 and 2, respectively, where the lowest binding energy (BE) in kcal/mol, number of candidate poses, and Mpro residues involved in hydrogen bonds with each compound are included for the selected clusters. In the last column of these Tables, the total IFIE in kcal/mol for each compound with all Mpro residues, evaluated using the ab initio FMO method is listed. Notably, Tables 1 and 2 indicate that the top-ranked cluster created by AutoDock4.2.6 did not necessarily correspond to the most stable structure in the FMO calculations. For example, as listed in Table 1, cluster 4 of compound A1 had the highest total IFIE, indicating that A1 was bound most strongly to the Mpro in the conformation of cluster 4, not in cluster 1. Therefore, Tables 1 and 2 suggested that the selection of clusters from the AutoDock4.2.6 results had to be done with caution. In the following analysis, we employed the cluster with the highest total IFIE.

### Binding affinities of the compounds and the main protease

The total IFIEs between the Mpro residues and the natural compounds extracted from Moringa oleifera [23], Aloe vera, and Nyctanthes arbor-tristis were compared, as shown in Fig. 3. The red bars indicate the compounds with the highest total IFIE from each plant. It should be noted that anthocyanin (N8) was excluded from the list of Mpro inhibitors because it had a positive charge and interacted differently with the Mpro residues compared with that of the other compounds.

As described in our previous study [23], of the 12 compounds from Moringa oleifera, niaziminin (M9) was found to bind more strongly to the Mpro (Table S4 of SM). This compound interacted strongly with the negatively charged Glu166 residue, resulting in a strong binding to the Mpro. The total IFIE was evaluated, having a magnitude of 136.5 kcal/mol, at least 17.5 kcal/mol higher than that of the other compounds extracted from Moringa oleifera. Therefore, we proposed novel compounds based on niaziminin (M9) to investigate whether the introduction of a hydroxyl group into niaziminin (M9) would enhance its binding affinity to the Mpro. Niaziminin (M9) is a thiocarbamate isolated from the leaves of Moringa oleifera [51]. The presence of an acetoxy group at the 4′-position of niaziminin (M9) is thought to be important for its ability to inhibit the activation of Epstein–Barr virus [52].

As indicated in Fig. 3, of the 34 remaining compounds after the exclusion of N8, compound feralolide (A14) from Aloe vera had the highest total IFIE (150.1 kcal/mol). This IFIE was approximately 13.6 kcal/mol greater than that of

[1] Springer
the compound with the total IFIE of the second-highest magnitude, i.e., niaziminin (M9) (136.5 kcal/mol) from *Moringa oleifera*. Aloesaponarin-I (A12) (122.6 kcal/mol) from *Aloe vera* had the total IFIE of the third-highest magnitude. Recently, Mpiana et al. [53] performed a molecular docking study with the Mpro using Gasteiger charges for 10 compounds extracted from *Aloe vera*, and the compound with the highest score in their study was feralolide (A14). Therefore, our present results obtained by ab initio FMO calculations are comparable to their results, suggesting that feralolide (A14) could be a potent inhibitor of the Mpro and therefore a drug lead compound against COVID-19.

To elucidate the reason for the strong binding affinity between feralolide (A14) and the Mpro, we investigated the IFIEs between the Mpro residues and feralolide (A14), eupatorin (A13), and aloesaponarin-I (A12), as these compounds had similar sizes among the 14 compounds extracted from *Aloe vera* as shown in Fig. 1. Feralolide (A14) (Fig. 4a) bound most strongly to Glu166 and also interacted with other Mpro residues Leu27, Asn142, and Leu167, resulting in a total IFIE of high magnitude. Therefore, these residues were found to be the main contributors to the strong interaction between the Mpro and feralolide (A14). In contrast, aloesaponarin-I (A12) (Fig. 4c) interacted strongly with only Glu166 and weakly with Asn142 and Gln189, resulting in a total IFIE of lower magnitude with the Mpro. As shown in Fig. 4b, the IFIEs of eupatorin (A13) with the Mpro were noticeably different from those of feralolide (A14) and aloesaponarin-I (A12). There was no strong interaction between eupatorin (A13) and the Mpro residues, and only Cys145 interacted with eupatorin (A13) at a higher magnitude than 10 kcal/mol. Therefore, the total IFIE of eupatorine (A13) was of a significantly lower magnitude than that of feralolide (A14) and aloesaponarin-I (A12). The comparison of Figs. 4a–c revealed that Glu166, Leu167, Leu27, and Asn142 were important for the strong binding of feralolide (A14) to the Mpro.

Therefore, we investigated the nature of the interactions between the Mpro residues and feralolide (A14), eupatorin (A13), aloesaponarin-I (A12) to understand which functional groups of the compound were responsible for the binding to the Mpro. As shown in Fig. 5a, two hydroxyl groups in the upper end of feralolide (A14) formed strong hydrogen bonds (1.51 and 1.59 Å) with Glu166 and the peptide backbone between Glu166 and Leu167. In addition, the carbonyl group of feralolide (A14) formed a hydrogen bond with the amide group of Asn142, while the hydroxyl group formed a hydrogen bond with the peptide backbone between Thr26 and Leu27. Aloesaponarin-I (A12) (Fig. 5c) formed only one strong hydrogen bond (1.57 Å) with Glu166. In contrast, as shown in Fig. 5b, there was no hydrogen-bonding interaction between eupatorin (A13) and the Mpro residues, although there were only weak electrostatic interactions with Thr26, Gly143, and Cys145. Conversely, Fig. 5a indicates that feralolide (A14) possessed many groups for strong binding with the Mpro residues. In particular, the two hydroxyl groups in the upper end effectively strengthened the interaction between feralolide (A14) and the Mpro residues. Therefore, feralolide (A14) was expected to be a drug lead compound for the development of potent inhibitors against COVID-19.

Aloesaponarin-I (A12) and aloesaponarin-II (A8), shown in Fig. 1, are anthraquinones isolated from the roots of *Aloe vera*, and their antiviral activity against the human influenza
Fig. 4 The IFIEs between the Mpro residues and the compounds from *Aloe vera*: (a) feralolide (A14), (b) eupatorin (A13), and (c) aloesaponarin-I (A12). The total IFIEs of these compounds with the Mpro residues are also shown. The red bars indicate the Mpro residues with the negative IFIEs whose magnitude was higher than 10 kcal/mol.

Fig. 5 Models of the molecular interactions of the selected *Aloe vera* compounds (ball-and-stick models) with the important key residues of Mpro (stick models): (a) feralolide (A14), (b) eupatorin (A13), and (c) aloesaponarin-I (A12). The hydrogen bonding and electrostatic interactions are indicated by red and blue lines, respectively.

Fig. 6 The IFIEs of anthocyanin (N8) from *Nyctanthes arbor-tristis* with the Mpro residues; anthocyanin (N8) has a charge of +1. Below is a model of the molecular interaction of anthocyanin (N8) (ball-and-stick model) and the important residues of Mpro (stick models). The electrostatic interactions are indicated by blue lines.
A virus was demonstrated in a previous study [54]. In addition, Parvez et al. [55] tested the anti-hepatitis B virus (HBV) potential of Aloe vera extract and its anthraquinones in hepatoma cells. They reported that the effect of aloe-emodin (A10) is comparable with that of lamivudine (a nucleoside reverse transcriptase inhibitor approved for the treatment of HBV) and appears to be the most promising natural anti-HBV drug, with CYP3A4 activation enhancing its therapeutic efficacy. Our present results (Fig. 3) indicated that aloesaponarin-I (A12) had the second-highest total IFIE of the compounds from Aloe vera, while aloesaponarin-II (A8) had an average-sized total IFIE. Therefore, it was expected from the total IFIE evaluated by the FMO method that aloesaponarin-I (A12) could also be a potent inhibitor of the Mpro.

In addition, we analyzed the interactions of the other compounds with a size of total IFIE larger than 100 kcal/mol with the Mpro. As shown in Fig. 3, the Aloe vera compounds caffeic acid (A2), esculetin (A6), aloe-emodin (A10), aloesaponarin-I (A12), and feralolide (A14) came into this category. Since esculetin (A6), a coumarin derivative found in various medicinal plants, inhibits proliferation and induces apoptosis in many types of human cancer cells, it is a promising chemotherapeutic agent [56]. In addition, esculetin (A6) has been widely used as an anti-inflammatory, antioxidant, antibacterial, and anti-diabetic therapeutic [57]. Recently, the anti-HBV activity of esculetin (A6) was investigated, and it was shown to inhibit HBV replication effectively both in vitro and in vivo [58]. Here, of the 14 compounds from Aloe vera, esculetin (A6) exhibited the IFIE of the highest magnitude (73 kcal/mol) with Glu166 and formed two hydrogen bonds. These results indicated that hydrogen bonding to Glu166 is a key for Aloe vera compounds to bind strongly to the Mpro. According to Juárez-Saldívar et al. [59], Glu166 is important for maintaining the shape of the Mpro active site. In addition to this hydrogen bond, most of the Aloe vera compounds participate in electrostatic interactions with Gly143, Ser144, and Cys145. In contrast, Nguyen et al. [60] found that Gly143 of the Mpro is the most important residue for hydrogen bonding with ligands, followed by Glu166, Cys145, and His163.

Table 2 lists the results of the docking and FMO calculations for the nine compounds extracted from Nyctanthes arbor-tristis. From the two or three clusters for each compound, we selected the cluster with the total IFIE of the highest magnitude and compared the magnitude of this IFIE for each compound. As shown in Fig. 3, the magnitudes of the total IFIE of the Nyctanthes arbor-tristis compounds, excluding N8, were significantly lower than those of the Aloe vera compounds. Actually, N8 had the highest total IFIE of all the compounds investigated here. However, this strong interaction came from the electrostatic interaction of the positive charge on N8 with the negatively charged residues of the
Mpro, as shown in Fig. 6. Therefore, the electrostatic nature of this interaction of N8 with the Mpro was significantly different from that of the other compounds; thus, in the present study, we eliminated N8 from the list of Mpro inhibitors.

Of the eight remaining compounds from Nyctanthes arbor-tristis, apigenin (N9) exhibited a total IFIE of high magnitude (94.8 kcal/mol). As indicated in Fig. 7a, apigenin (N9) interacted strongly only with Glu166 via electrostatic interactions, suggesting that Glu166 is a key residue for stabilizing bound apigenin (N9). However, no residue other than Glu166 interacted strongly with apigenin (N9), resulting in the lower magnitude of its total IFIE compared with that of feralolide (A14) and aloesaponarin-I (A12). Previously, the antiviral activity of the naturally occurring flavonoid apigenin (N9) was investigated in vitro and in vivo against several viruses including enterovirus 71, hepatitis C virus, human immunodeficiency virus, and adenoviruses [61]. Therefore, it was expected that apigenin (N9) could also be an inhibitor of the Mpro, although its binding affinity to the Mpro is likely to be lower than those of feralolide (A14) and aloesaponarin-I (A12).

![Visualization of the clustering of compounds using a visualized cluster analysis of protein–ligand interaction [62]. Each compound is represented in the vertical axis. The horizontal axis on the right represents the Mpro residues existing within 10 Å of the compound. Red and blue colors represent attractive and repulsive interactions, respectively, and the shading represents the magnitude of the absolute IFIE value. The tree on the left indicates the clustering of compounds based on the IFIEs with the Mpro residues. Compounds in the upper group have strong attractive interaction with Glu166](image-url)
The IFIEs between Mpro residues and long-chain fatty acids such as pelargonic acid (N2) and myristic acid (N3) were also compared. As indicated in Fig. 7b, myristic acid (N3) interacted strongly only with Glu166 and Leu141 of the Mpro and had a total IFIE of lower magnitude compared with that of apigenin (N9). Therefore, we considered that these long-chain fatty acids are not suitable for the potent inhibitors against the Mpro.

To explain the weaker binding of apigenin (N9) to the Mpro compared with that of feralolide (A14), we analyzed the specific interactions of the compounds with the main protease.

To elucidate the difference in the specific interactions of the 35 natural compounds contained in *Moringa oleifera*, *Aloe vera*, and *Nyctanthes arbor-tristis* with the Mpro residues, we classified these compounds based on their IFIEs using the visualized cluster analysis of protein–ligand interactions [62]. In this analysis, the ligands were classified into different groups depending on the similarity of the IFIEs of each ligand with the Mpro residues in the ligand-binding site. We eliminated N8 as a candidate inhibitor of the Mpro because it is positively charged and its way of interaction with the Mpro residues was significantly different from that of the other compounds.

As shown in Fig. 9, the compounds were classified into two main groups depending on the nature of their interaction with Glu166 in the Mpro binding site. Feralolide (A14), which had the highest total IFIE among the compounds investigated here, was classified in the upper group in Fig. 9, in which all compounds interacted strongly with Glu166. Within this group, only feralolide (A14) formed a subgroup, while the other compounds formed a completely different subgroup, indicating that no other compounds had similar interactions with the Mpro residues compared to feralolide (A14). In contrast, niaziminin (M9), which had the total IFIE of the second-highest magnitude, belonged to the same subgroup of aloesaponarin-I (A12). Therefore, it was revealed from Fig. 9 that the IFIEs between Mpro residues and niaziminin (M9) and aloesaponarin-I (A12) were similar although these compounds had different chemical structures.

To understand the reason for these differences in IFIEs, we compared the interactions of these compounds with the key residues in the Mpro binding site. As shown in Fig. 5a, the hydroxyl groups at one end of feralolide (A14) formed hydrogen bonds with the negatively charged Glu166, whereas that at the other end formed hydrogen bonds with the peptide backbone between Thr26 and Leu27. These hydrogen bonds of feralolide (A14) with two separate sites...
in the Mpro-binding pocket were achieved by its vertical conformation in the binding pocket, as shown in Fig. 10a. Notably, of all compounds investigated in the present study, only feralolide (A14) was bound in this conformation. Feralolide (A14) also formed a weak hydrogen bond with Asn142. In contrast, Fig. 10b indicates that niaziminin (M9) and aloesaponarin-I (A12) were bound in a perpendicular conformation in the binding pocket, interacting with Glu166, Gln189, and Asn142. As these compounds did not interact with Thr26 and Leu27, their binding properties were not similar to those of feralolide (A14). The magnitude of the total IFIE of aloesaponarin-I (A12) with the Mpro was the third highest among the compounds employed in this study. Therefore, aloesaponarin-I (A12) is also expected to be a potent inhibitor against the Mpro in addition to feralolide (A14) and niaziminin (M9).

**Proposal of novel compounds based on feralolide (A14) and niaziminin (M12)**

In our previous molecular simulations [23], we investigated the binding properties of 12 compounds extracted from *Moringa oleifera* with the Mpro and found that, niaziminin (M9) is bound most strongly to the Mpro. The chemical structures of the 12 compounds and the results of the simulations are shown in Fig. S1 and Tables S1 and S2 of SM. In addition, we proposed novel compounds based on niaziminin (M9) and revealed that the introduction of a hydroxyl group into niaziminin (M9) enhanced its binding to the Mpro.

In the present study, we first attempted to propose candidate potent inhibitors of the Mpro based on feralolide (A14), which had the total IFIE of the highest magnitude among the compounds studied here, as shown in Fig. 3. We replaced each hydrogen atom of feralolide (A14) with a hydroxyl group to propose nine novel compounds and investigated their binding properties with the Mpro in the same conformation of feralolide (A14). To obtain the stable structures of the Mpro complexes with these proposed compounds, we optimized their structures using the MM method in water. In addition, the total IFIEs between the Mpro and the compounds were evaluated using the FMO method to propose novel inhibitors with higher binding affinity to the Mpro. As shown in Table 3, the total IFIE was changed significantly depending on the hydroxylation site. In particular, the magnitude of the total IFIEs of feralolide derivatives (A14b), (A14d), and (A14i) were higher than 160 kcal/mol and at least 10 kcal/mol higher than that of feralolide (A14), indicating that the introduction of a hydroxyl group could significantly enhance the binding of feralolide derivatives to the Mpro.

To increase our understanding of this enhancement, we compared the IFIEs of each compound with the Mpro residues. As shown in Fig. 11a, feralolide (A14) interacted strongly with Glu166, Leu167, Leu27, and Asn142. By introducing a hydroxyl group in the d-site of feralolide (A14d), the IFIE between Glu166 and feralolide (A14) was further enhanced by 30 kcal/mol as shown in Fig. 11c, resulting in the total IFIE of A14d having the highest magnitude of 171.1 kcal/mol. In contrast, as shown in Fig. 11b–d, the introduction of a hydroxyl group in the b-site or i-site of feralolide (A14) enhanced the IFIE with Gln189 or Cys145 although the effect was not as strong as that seen with feralolide derivative (A14d). Therefore, the hydroxylation in the d-site of A14 was found to be most effective for enhancing the binding between feralolide (A14) and the Mpro.

**Table 3** This table shows the total IFIE (kcal/mol) of feralolide (A14) and its proposed compounds with the Mpro, evaluated using the FMO method. The proposed compounds are defined as the compounds A14a–A14i depending on the hydroxylation site. For example, in the compound (A14a), the hydrogen atom at the a-site of A14, as shown below, is replaced by a hydroxyl group

| Compound | Total IFIE |
|----------|------------|
| A14      | −150.1     |
| A14a     | −148.9     |
| A14b     | −168.7     |
| A14c     | −154.0     |
| A14d     | −171.1     |
| A14e     | −154.8     |
| A14f     | −159.9     |
| A14g     | −153.5     |
| A14h     | −154.5     |
| A14i     | −160.9     |
To understand this enhancement, we investigated the interactions of the proposed feralolide derivatives with some key residues of the Mpro. As shown in Fig. 5a, feralolide (A14) formed hydrogen bonds with Glu166, Asn142, and the peptide backbones between Glu166 and Leu167 and between Thr26 and Leu27. In the complex with feralolide derivative (A14d) (Fig. 12b), the extra hydroxyl group created an additional hydrogen bond with Glu166. As a result, the IFIE of Glu166 was significantly enhanced as shown in Fig. 11c. In contrast, Fig. 12a indicates that if the b-site was hydroxylated to produce feralolide derivative (A14b), this formed a new hydrogen bond with Gln189, leading to the enhancement of IFIE with Gln189. As the hydroxyl group of feralolide derivative (A14i) interacted electrostatically with Cys145, as shown in Fig. 12c, the IFIE of Cys145 was enhanced in feralolide derivative (A14i), as indicated in Fig. 11d. As mentioned above, depending on the site of hydroxylation on feralolide (A14), the interactions of the feralolide (A14) derivatives with some key residues of the Mpro were significantly changed. Of the proposed feralolide (A14) derivatives, the derivative (A14d) was found to have the total IFIE of the highest magnitude with the Mpro residues, indicating that it could be a candidate compound as a potent inhibitor of the Mpro.

Next, we proposed novel derivatives of niazirinin (M12) and investigated their binding properties to the Mpro because niazirinin (M12) had the total IFIE of the second-highest magnitude of the compounds extracted from *Moringa oleifera*, as shown in Fig. 3. One hydrogen atom of niazirinin (M12) was replaced by a hydroxyl group to create candidate compounds, and their total IFIEs with the Mpro were investigated. As indicated in Table S5 of SM, only niazirinin derivatives (M12c) and (M12d) had higher total IFIEs compared with niazirinin (M12). However, the magnitude of the total IFIEs of the niazirinin derivatives (M12c) and (M12d) was lower than that (150 kcal/mol) of feralolide (A14). Therefore, it was revealed that the derivatization of niazirinin (M12) by the introduction of a hydroxyl group was not as effective for enhancing the binding affinity to the Mpro, compared with the derivatives of feralolide (A14).

To understand the change in the total IFIE is due to the introduction of an extra hydroxyl group into niazirinin (M12), we compared the IFIEs to the Mpro residues for niazirinin (M12) and derivatives (M12c) and (M12d). As shown in Fig. S2a of SM, niazirinin (M12) formed a strong hydrogen bond with Glu166 and interacted electrostatically with Asn142 and Gly143. As shown in Fig. S2b, the hydroxyl group at the c-site of M12 was, at most, 5 kcal/mol for Cys145 (Fig. S2b). In contrast, the hydroxylation at the d-site significantly enhanced the interactions of niazirinin (M12) with the residues Leu141 and Glu166 (Fig. S2c). However, the interactions of niazirinin (M12) with some residues around Leu141 were weakened by the hydroxylation, resulting only a small enhancement of the total IFIE for the niazirinin derivative (M12d).

Therefore, we investigated the nature of the interactions of Mpro key residues with niazirinin (M12) and derivatives (M12c) and (M12d). As shown in Fig. S3a of SM, niazirinin (M12) formed a strong hydrogen bond with Glu166 and interacted electrostatically with Asn142 and Gly143. As shown in Fig. S3b, the hydroxyl group...
introduced at the c-site of niazirinin (M12) interacted electrostatically with Cys145. In addition, a hydrogen bond was formed with a distance of 1.65 Å between the Glu166 side chain and a hydroxyl group of another site on the niazirinin derivative (M12c). The electrostatic interactions with the Leu141–Asn142–Gly143 peptide were also enhanced, as shown in Fig. S3b. These changes in interactions in the binding site were considered to cause a significant (about 20 kcal/mol) increase in the total IFIE of the niazirinin derivative (M12c). In contrast, the hydroxyl group introduced at the d-site of niazirinin (M12d) formed a strong hydrogen bond with the peptide backbone between Phe140 and Leu141 (Fig. S3c). In addition, an extra hydrogen bond was formed between the niazirinin derivative (M12d) and Glu166, resulting in the enhancement of the IFIE for Glu166. However, as shown in Fig. S2b, c, the effect of introducing a hydroxyl group to niazirinin (M12) on the interactions between M12 and the Mpro was found to be at most 12 kcal/mol, which
was less significant than that (at most 30 kcal/mol) for the hydroxylated feralolide (A14) derivatives shown in Fig. 11. To elucidate which compound proposed in our study was bound more strongly to the Mpro, we compared their total IFIEs in Fig. 13. Niaziminin derivative (M9d) and feralolide derivatives (A14d), (A14b) had total IFIEs with a rather higher magnitude compared to those of the other compounds, indicating that they were expected to be the potent inhibitors of the Mpro. To confirm the stability of binding for these compounds to the Mpro, we conducted 100 ns MD simulations for the complexes of Mpro with each of these compounds at 310 K, within an explicit water box using the MD simulation program package GROMACS 2018.4 [63]. The root mean square deviation (RMSD) from the initial structure of the MD simulations were compared in Fig. 14 for the Mpro complexes with A14, A14b, and A14d. Although the RMSDs increased rapidly to 2–4 Å during the initial 1 ns, there is no significant increase during the MD simulations from 20 to 100 ns. It was confirmed that A14, A14b, and A14d stayed in the ligand-binding pocket of the Mpro even at 100 ns. Figure 14 also indicated that RMSDs for the A14b and A14d complexes were significantly smaller than that of the A14 complex. This result can be explained by the trend in the magnitude of the total IFIEs of the complexes shown in Table 3. Their total IFIEs evaluated in the present study are –171.1 (A14d), –168.7 (A14b), and –150.1 (A14), respectively, indicating that A14d and A14b can bind more strongly to the ligand-binding pocket of the Mpro and stay at the same position compared with A14. In addition, we carried out the same MD simulations for the Mpro complexes with M9/M9d compound. As shown in Fig. S4, the RMSD values of the complexes have no significant increase during the MD simulations from 10 to 100 ns.

Moreover, we investigated the root mean square fluctuation (RMSF) of each Mpro residue and the compound for the Mpro complexes, to elucidate which residues or compounds fluctuate more significantly during the MD simulations. The results for the A14 and M9 derivatives are shown in Figs. 15 and S5, respectively. As indicated in Fig. 15, for the Mpro complexes with the A14 derivatives, although the C- and N-terminal residues had rather large RMSFs, the RMSFs of the other residues are smaller than 4 Å. And the RMSFs of the compounds were found to be 1.46 (A14), 2.61 (A14b), and 0.85 Å (A14d), respectively. Similar results were obtained for the Mpro complexes with the M9/M9d compound as shown in Fig. S5. These MD results revealed that the compounds can stay at the binding pocket of the Mpro even at 310 K. Therefore, we concluded that our proposed A14b, A14d, and M9d compounds are expected to be potent inhibitors against the Mpro.
Conclusions

To find novel potent inhibitors of the SARS-CoV-2 Mpro, we investigated the binding properties between the Mpro and the 35 compounds extracted from *Moringa oleifera*, *Aloe vera*, and *Nyctanthes arbor-tristis*, using molecular simulations based on protein–ligand docking, MM optimizations, and ab initio FMO calculations. The FMO results revealed...
that feralolide (A14) from *Aloe vera* bound most strongly to the Mpro, making it a promising Mpro inhibitor candidate. To enhance the binding affinity of feralolide (A14), we sequentially substituted a hydroxyl group for each of the hydrogens in the feralolide (A14) structure. We repeated this process for niaziminin (M9) and niazirinin (M12) from *Moringa oleifera* and investigated the binding properties of their derivatives with the Mpro. The results elucidated that feralolide derivative (A14d) shown in Table 3 as well as our previously proposed niaziminin derivative (M9d) [23] bound strongly to the Mpro. Therefore, these derivatives are expected to be potent inhibitors of the Mpro.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s11224-022-02021-y.

**Author contribution** DS: Data collection, simulations, analysis, and writing of an original draft. RS, SY, DO: Simulations, analysis of results, and creation of tables and figures. NK: Supervision, validation, revision, and edition of the manuscript, tables, and figures.

**Funding** This work was supported by the DAIKO FOUNDATION.

**Data availability** All data simulated or analyzed during this study are included in this article and the supplementary materials.

**Code availability** Not applicable.

**Declarations**

**Competing interests** The authors declare no competing interests.

**References**

1. Hui DS, Azhar EI, Madani TA et al (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91:264–266
2. Ullrich S, Nitsche C (2020) The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 30:127377
3. Suárez D, Díaz N (2020) SARS-CoV-2 main protease: a molecular dynamics study. J Chem Inf Model 60:5815–5831
4. Mazzini S, Musso L, Dallavalle S, Artali R (2020) Putative SARS-CoV-2 Mpro inhibitors from an in-house library of natural and nature-inspired products: a virtual screening and molecular docking study. Molecules 25:3745
5. Mengist HM, Dihnessa T, Jin T (2021) Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Front Chem 9:622898
6. Abouelela ME, Assaf HK, Abdelhamid RA et al (2021) Identification of potential SARS-CoV-2 main protease and spike protein inhibitors from the genus aloe: an in silico study for drug development. Molecules 26:1767
7. Fitzgerald M, Heinrich M, Booker A (2019) Medicinal plant analysis: a historical and regional discussion of emerging complex techniques. Front Pharmacol 10:1480
8. Mpiana PT, Ngbolua K-T-N, Tshibangu DST et al (2020) Aloe vera (L.) Burm. F. as a potential anti-COVID-19 plant: a mini-review of its antiviral activity. European J Med Plants 31:86–93
9. Guo X, Mei N (2016) Aloe vera: a review of toxicity and adverse clinical effects. J Environ Sci Health C 34:77–96
10. Surjushe A, Vasani R, Saple DG (2008) Aloe vera: a short review. Indian J Dermatol 53:163–166
11. Hęś M, Dziedzic K, Górecka D et al (2019) Aloe vera (L.) Webb.: Natural sources of antioxidants - a review. Plant Foods Hum Nutr 74:255–265
12. Sharrif Moghaddasi M, Res M (2011) Aloe vera their chemicals composition and applications: a review. Med Chem Res 2:466–471
13. Lowe H, Steele B, Bryant J et al (2021) Antiviral activity of Jamaican medicinal plants and isolated bioactive compounds. Molecules 26:607
14. Sydiskis RJ, Owen DG, Lohr JL et al (1991) Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrob Agents Chemother 35:2463–2466
15. Saoo K, Miki H, Ohmori M, Winters WD (1996) Antiviral activity of aloe extracts against cytomegalovirus. Phytother Res 10:348–350
16. Rezzazadeh F, Moshaoverinia M, Motamedifar M, Alyaseri M (2016) Assessment of anti-HSV-1 activity of aloe vera gel extract: an in vitro study. J Dent 17:49–54
17. Gansukh E, Gopal J, Paul D et al (2018) Ultrasound mediated accelerated anti-influenza activity of aloe vera. Sci Rep 8:17782
18. Hirermath V, Hiremath BS, Mohapatra S, Das AK (2016) Literature review of parijata (Nyctanthes Arbofris Linn.) an herbal medicament with special reference to Ayurveda and botanical literatures. Biomed Pharmacol J 9:1019–1025
19. Bhalakhiya H, Modi NR (2019) Traditional medicinal uses, phytochemical profile and pharmacological activities of Nyctanthes arbor-tristis. RJLBPCS 5:1003–1023
20. Jain PK, Pandey A (2016) The wonder of ayurvedic medicine-Nyctanthes arbor-tristis. Int J Herb Med 4:9–17
21. Gupta P, Bajpai SK, Chandra K et al (2005) Antiviral profile of Nyctanthes arbor-tristis L. against encephalitis causing viruses. Indian J Exp Biol 43:1156–1160
22. Rani C, Chawla S, Mangal M et al (2012) Nyctanthes arbor-tristis Linn. (Night Jasmine): a sacred ornamental plant with immense medicinal potentials. Ind J Tradit Knowl 11:427–435
23. Shaji D, Yamamoto S, Saito R et al (2021) Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: molecular docking and ab initio fragment molecular orbital calculations. Biophys Chem 275:106608
24. Quispe C, Villalobos M, Bórquez J, Simirgiotis M (2018) Chemical composition and antioxidant activity of aloe vera from the pica oasis (Tarapacá, Chile) by UHPLC-Q/Orbitrap/MS/MS. J Chem 2018:6123850
25. Kahramanoğlu I, Chen C, Chen J, Wan C (2019) Chemical constituents, antimicrobial activity, and food preservative characteristics of aloe vera gel. Agron 9:831
26. Hamman JH (2008) Composition and applications of aloe vera leaf gel. Molecules 13:1599–1616
27. Gulshan B, Suri KA, Parul G (2015) A comprehensive review on Nyctanthes arbor-tristis. Int J Drug Dev Res 7:183–193
28. Karthick V, Venkataredy G, Dhariani J, Ravi S (2019) Study on the chemical constituents of the essential oil from nyctanthes arbor-tristis and its molecular docking studies. Asian J Pharm Clin Res 12:195–199
29. Benefit D (2019) Anticancer activity of nyctanthes arbor-tristis. Int J Adv Res Ideas Innov Technol 5:84–87
30. Srivastava AK, Kumar A, Misra N (2020) On the inhibition of COVID-19 protease by Indian herbal plants: an in silico investigation. https://arxiv.org/abs/2004.03411
31. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235–249
32. Kim S, Thiessen PA, Bolot EE et al (2016) PubChem substance and compound databases. Nucleic Acids Res 44:D1202–D1213
33. Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717
34. Frisch MJ, Trucks GW, Schlegel HB et al (2009) Gaussian 09, Revision D. 01, Gaussian, Inc., Wallingford CT
35. Besler BH, Merz KM, Kollman PA (1990) Atomic charges derived from semiempirical methods. J Comput Chem 11:431–439
36. Jin Z, Du X, Xu Y et al (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289–293
37. Berman HM, Westbrook J, Feng Z et al (2000) The protein data bank. Nucleic Acids Res 28:235–242
38. Søndergaard CR, Olsson MHM, Rostkowski M, Jensen JH (2011) Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa Values. J Chem Theory Comput 7:2284–2295
39. Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput 7:525–537
40. Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDocktools4: Automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791
41. Case DA, Cheatham T, Darden T et al (2005) The AMBER biomolecular simulation programs. J Comput Chem 26:1668–1688
42. Lindorff-Larsen K, Piana S, Palmo K et al (2010) Improved sidechain torsion potentials for the amber ff99SB protein force field. Proteins 78:1950–1958
43. Jorgensen WL, Chandrasekhar J, Madura JD et al (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926–935
44. Wang J, Wolf RM, Caldwell JW et al (2004) Development and testing of a general amber force field. J Comput Chem 25:1157–1174
45. Kitaura K, Ikeo A, Asada T et al (1999) Fragment molecular orbital method: an approximate computational method for large molecules. Chem Phys Lett 313:701–706
46. Fukuzawa K, Komeiji Y, Mochizuki Y et al (2006) Intra and intermolecular interactions between cyclic-AMP receptor protein and DNA: ab initio fragment molecular orbital study. J Comput Chem 27:948–960
47. Mochizuki Y, Nakano T, Koikegami S et al (2004) A parallelized integral-direct second-order Møller-Plesset perturbation theory method with a fragment molecular orbital scheme. Theor Chem Acc 112:442–452
48. Mochizuki Y, Koikegami S, Nakano T et al (2004) Large scale MP2 calculations with fragment molecular orbital scheme. Chem Phys Lett 396:473–479
49. Mochizuki Y, Yamashita K, Nakano T et al (2011) Higher-order correlated calculations based on fragment molecular orbital scheme. Theor Chem Acc 130:515–530
50. Kobayashi I, Takeda R, Suzuki R et al (2017) Specific interactions between androgen receptor and its ligand: ab initio molecular orbital calculations in water. J Mol Graph Model 75:383–389
51. Faizi S, Siddiqui BS, Saleem R et al (1992) Isolation and structure elucidation of novel hypotensive agents, niazin A, niazin B, niazimicin and niaziminin A B from moringa oleifera: the first naturally occurring thiocarbamates. J Chem Soc Perkin Trans I 23:3237–3241
52. Murakami A, Kitazono Y, Jiwajinda S et al (1998) Niaziminin, a thiocarbamate from the leaves of moringa oleifera, holds a strict structural requirement for inhibition of tumor-promoter-induced Epstein-Barr virus activation. Planta Med 64:319–323
53. Mpiana PT, Ngbolua K-T-N, Tshibangu DST et al (2020) Identification of potential inhibitors of SARS-CoV-2 main protease from aloe vera compounds: a molecular docking study. Chem Phys Lett 754:137751
54. Borges-Argáez R, Chan-Balan R, Cetina-Montejo L et al (2019) In vitro evaluation of anthraquinones from aloe vera (Aloe barbadensis Miller) roots and several derivatives against strains of influenza virus. Ind Crops Prod 132:468–475
55. Parvez MK, Al-Dosari MS, Alam P et al (2019) The anti-hepatitis B virus therapeutic potential of anthraquinones derived from aloe vera. Phytother Res 33:2960–2970
56. Cho JH, Shin JC, Cho JJ et al (2015) Esculetin (6,7-dihydroxycoumarin): a potential cancer chemopreventive agent through suppression of Sp1 in oral squamous cancer cells. Int J Oncol 46:265–271
57. Liang C, Ju W, Pei S et al (2017) Pharmacological activities and synthesis of esculetin and its derivatives: a mini-review. Molecules 22:387
58. Huang SX, Mou JF, Luo Q et al (2019) Anti-hepatitis B virus activity of esculetin from Microsorum fortunei in vitro and in vivo. Molecules 24:3475
59. Juárez-Saldívar A, Lara-Ramírez EE, Reyes-Espinosa F et al (2020) Ligand-based and structure-based in silico repurposing approaches to predict inhibitors of SARS-CoV-2 Mpro protein. Sci Pharm 88:54
60. Nguyen DD, Gao K, Chen J et al (2020) Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning. Chem Sci 11:12036–12046
61. Wang L, Song J, Liu A et al (2020) Research progress of the antiviral bioactivities of natural flavonoids. Nat prod Bioprospect 10:271–283
62. Amari S, Aizawa M, Zhang J et al (2006) VISCANA: Visualized cluster analysis of protein−ligand interaction based on the ab initio fragment molecular orbital method for virtual ligand screening. J Chem Inf Model 46:221–230
63. Borges-Argáez R, Chan-Balan R, Cetina-Montejo L et al (2019) In vitro evaluation of anthraquinones from aloe vera compounds: a molecular docking study. Chem Phys Lett 754:137751
64. Berendsen HJ, van der Spoel D, van Drunen R (1995) GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun 91:43–56

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.